TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12672184
Drug: Ro 45‐2081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 45‐2081 (high dose 0.5 mg/kg, maximum 50 mg)
Study: 8704438
Drug: Yangxueshengru Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxueshengru Oral Liquor (YXSR)
Study: 2666884
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 2 g cefotetan
Study: 2666884
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose of 1 g intravenous cephazolin
Study: 28724846
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg three times daily for nine months)
Study: 28724846
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 or 15 mg once daily for nine months)
Study: 24300630
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential treatment
Study: 24300630
Drug: 10-day conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day conventional treatment
Study: 31982359
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pregabalin
Study: 21786524
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg midazolam (placebo)
Study: 17924845
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II)
Study: 17924845
Drug: Immediate curative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate curative therapy without CAB (Group I)
Study: 15083959
Drug: Daily OL-HDF
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily OL-HDF (2 to 2.5 hours, six times per week)
Study: 15083959
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly OL-HDF (4 to 5 hours) - Control group
Study: 31045589
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg/d)
Study: 24169302
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (3.5 mL of autologous platelets buffered with 8.4% sodium bicarbonate)
Study: 24169302
Drug: Glucocorticoid (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (GC) injection (1 mL triamcinolone, 40 mg/mL + 2 mL lidocaine, 10 mg/mL)
Study: 24169302
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (3 mL saline, 0.9%)
Study: 17924889
Drug: Continuous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous remifentanil infusion
Study: 16717305
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine alone
Study: 16935471
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 3% VC-IP cream for 3 weeks
Study: 10598693
Drug: Combination (COSOPT)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (COSOPT)
Study: 29255098
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules (24 × 10^9 colony-forming units of lactobacilli and bifidobacteria)
Study: 29255098
Drug: Sorbitol gum
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol gum (5 pieces daily)
Study: 29255098
Drug: Xylitol gum
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol gum (15% xylitol; 5 pieces daily)
Study: 23297867
Drug: Methylphenidate (Concerta®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (Concerta®), up-titrated over 2 weeks to a maximum dose of 54 mg daily for 20 weeks, given under daily supervision.
Study: 23297867
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered under the same conditions as methylphenidate.
Study: 21894705
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) with Sufentanil
Study: 19850248
Drug: Reduced-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose reteplase + abciximab
Study: 17234657
Drug: High-selenium yeast
Normalized name: HIGH SELENIUM YEAST
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-selenium yeast preparation (100 microg daily, n=99)
Study: 15293890
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate days (n = 17)
Study: 15293890
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate months (n = 12)
Study: 9403933
Drug: Topical dinitrochlorobenzene
Normalized name: Dichlorobenzene
DrugBank: Dichlorobenzene (DB14046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dinitrochlorobenzene (DNCB) therapy
Study: 9403933
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DNCB therapy)
Study: 7981429
Drug: MK-679 500
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-679 500 mg
Study: 8389106
Drug: MK-679 125
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-679 125 mg
Study: 3549028
Drug: Tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 0.05 mg X kg‐1
Study: 31551217
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment (Control)
Study: 28221247
Drug: eHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth intervention using the web-application young.constant-care.com (YCC) on a monthly basis and during flare-ups, with annual outpatient visits.
Study: 16677182
Drug: Oral functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral functional training plus high-calorie and high-protein diet
Study: 16677182
Drug: High-calorie and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie and high-protein diet (supplement group)
Study: 15290410
Drug: Epinephrine group
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine group (n = 10) received 14 mg of tetracaine and 0.2 mg of epinephrine
Study: 15290410
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 10) received 14 mg of tetracaine
Study: 9666867
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (0.25 IU/kg/week)
Study: 10741688
Drug: Placebo (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (first 6 months) then switched to GH therapy
Study: 2803050
Drug: Piracetam 8
Normalized name: piracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 8 g
Study: 26180352
Drug: Flexion-distraction manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexion-distraction manipulation therapy combined with conservative physical therapy
Study: 26180352
Drug: Conservative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative physical therapy
Study: 10754625
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream and plastic occlusive dressing
Study: 10754625
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and plastic occlusive dressing
Study: 10754625
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream and plastic occlusive dressing for 60 min
Study: 8970892
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral phosphate dose (1500 mg in water)
Study: 8970892
Drug: Three consecutive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive oral phosphate doses (3 x 500 mg in water)
Study: 1728934
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg gemfibrozil (two 300 mg capsules twice daily)
Study: 1728934
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg gemfibrozil (one 600 mg tablet twice daily)
Study: 1728934
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg gemfibrozil (two 450 mg tablets in the evening)
Study: 1728934
Drug: gemfibrozil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (all formulations)
Study: 1728934
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg gemfibrozil
Study: 6365235
Drug: Oral amoxycillin
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amoxycillin (3 g) and clavulanate (250 mg)
Study: 6365235
Drug: Intramuscular procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular procaine penicillin (2.4 MU)
Study: 26717223
Drug: 60-mg prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg prasugrel loading dose
Study: 26717223
Drug: Clopidogrel standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel standard dose
Study: 21800004
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day n3‐PUFA
Study: 19501883
Drug: Doxazosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin plus tenoxicam 20 mg
Study: 12401122
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg
Study: 10681323
Drug: Lamivudine 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 0.35 mg/kg twice daily
Study: 10681323
Drug: Lamivudine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 1.5 mg/kg twice daily
Study: 10681323
Drug: Lamivudine 4
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 4 mg/kg twice daily
Study: 10681323
Drug: Lamivudine 3
Normalized name: lamivudine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 3 mg/kg once daily
Study: 10681323
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg (tablets) for adolescents
Study: 9322520
Drug: Lamivudine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (all doses)
Study: 10681323
Drug: Lamivudine 3
Normalized name: lamivudine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 3 mg/kg/day
Study: 15078377
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (1 mg/kg)
Study: 9316958
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia (1 ml/kg 0.20% bupivacaine with 1/200,000 epinephrine)
Study: 25815324
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein daily
Study: 25815324
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lutein daily
Study: 25815324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 mg lutein and 10 mg zeaxanthin daily
Study: 21925062
Drug: MLC601 (NeuroAiD™),
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLC601 (NeuroAiD™), 4 capsules, 3 times a day for 3 months
Study: 21925062
Drug: Placebo, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 capsules, 3 times a day for 3 months
Study: 18283598
Drug: Levonorgestrel administered
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel administered alone
Study: 18283598
Drug: Mifepristone (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (selective progesterone receptor modulator)
Study: 8794800
Drug: Dipyrone, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone, 2.5 g
Study: 8794800
Drug: Nitroglycerin, 1
Normalized name: Nitroglycerin, 100 mcg/mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin, 1 mg
Study: 8794800
Drug: N‐butylscopolamine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐butylscopolamine, 20 mg
Study: 8794800
Drug: Tramadol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol, 50 mg
Study: 8794800
Drug: Indomethacin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 75 mg
Study: 1616158
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium (n = 20)
Study: 1616158
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg succinylcholine (n = 10)
Study: 778987
Drug: Sulindac (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (400 mg/day)
Study: 1092727
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg/day)
Study: 26120052
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (intramuscular testosterone undecanoate for 40 weeks)
Study: 25070809
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) 100 mg/d
Study: 25070809
Drug: Modified Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Behavioral Self-Control Therapy (MBSCT)
Study: 25070809
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Compliance Enhancement Treatment (BBCET)
Study: 22585094
Drug: 20-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-week group treatment in addition to treatment as usual
Study: 9462588
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (APAs)
Study: 12836712
Drug: Enalapril therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril therapy
Study: 8046423
Drug: Quadrivalent vaccine
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent vaccine (1 x 10(4) PFU each of D x RRV and RRV, followed 4 weeks later by 1 x 10(4) PFU each of DS1 x RRV and ST3 x RRV)
Study: 8046423
Drug: Quadrivalent vaccine
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent vaccine (10(4) PFU of each component)
Study: 8046423
Drug: M37 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M37 vaccine (10(4) PFU)
Study: 8046423
Drug: Higher-titered quadrivalent
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-titered quadrivalent vaccine (10(5) PFU of each component)
Study: 8046423
Drug: Higher-titered M37
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-titered M37 vaccine (10(5) PFU)
Study: 2902873
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol
Study: 31868889
Drug: Therapy A
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy A - Bolus water drinking + physical counter‐manoeuvres (PCM)
Study: 31868889
Drug: Therapy B
Normalized name: Therapy Bayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy B - Bolus water drinking + PCM + abdominal compression
Study: 31868889
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy (bolus water drinking)
Study: 16645968
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid (5 mg)
Study: 9684701
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) (6,160 IU +/- 1,350 IU)
Study: 9684701
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) (15 anti-Xa U/kg + 5 anti-Xa U/kg/h)
Study: 2904367
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg kg‐1 (divided dose)
Study: 2904367
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg kg‐1 (divided dose)
Study: 2904367
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg kg‐1 (single dose)
Study: 2904367
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg kg‐1 (divided dose)
Study: 21270326
Drug: iv recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv recombinant hCG (1, 10, 25, 100, and 250 μg)
Study: 21270326
Drug: iv recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv recombinant hCG (25 μg)
Study: 19481579
Drug: Deltoid injection
Normalized name: Ambrosia deltoidea pollen
DrugBank: Ambrosia deltoidea pollen (DB10765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Study: 19481579
Drug: Gluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluteal injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Study: 19481579
Drug: Deltoid and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid and gluteal injections of paliperidone palmitate
Study: 16923411
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid multivitamin (5 mg folic acid, 50 mg vitamin B6, 1000 microg vitamin B12)
Study: 16923411
Drug: Low-dose folic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose folic acid multivitamin (0 mg folic acid, 1.4 mg vitamin B6, 2 microg vitamin B12)
Study: 14970765
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment using pulsed electromagnetic fields
Study: 14970765
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for patients with anterior disk displacement without reduction
Study: 14970765
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for patients with osteoarthritis
Study: 14970765
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for patients with anterior disk displacement with reduction
Study: 2330731
Drug: 1-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day treatment with sulfamerazine/trimethoprim (Berlocombin)
Study: 2330731
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment with regular sulfamerazine/trimethoprim (Berlocombin)
Study: 2330731
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment with reduced sulfamerazine/trimethoprim (Berlocombin)
Study: 24585363
Drug: Arthroscopic capsular
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic capsular release including release of the rotator interval and anterior and inferior capsule (Group I, n = 37)
Study: 24585363
Drug: Arthroscopic capsular
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic capsular release extended to the posterior capsule (Group II, n = 38)
Study: 29653649
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg BID
Study: 20141630
Drug: Cryotherapy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy using liquid nitrogen for a maximum of 4 treatments (2-3 weeks apart)
Study: 20141630
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid (50%) self-treatment for a maximum of 8 weeks
Study: 18043528
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for 12 weeks
Study: 16086929
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment arms
Study: 10354026
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further corticosteroid treatment (group C)
Study: 1354687
Drug: Tocopherol (dl-alpha-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol (dl-alpha-tocopherol nicotinate, 200 mg, tid)
Study: 1354687
Drug: Tocopherol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocopherol (200 mg, tid)
Study: 6499511
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg meptazinol every 3 to 6 hours as required for 72 hours
Study: 29042063
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (10 mL)
Study: 29042063
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (5 mL)
Study: 23050557
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum CJLP133 (0.5 × 10^10 CFU, twice a day for 12 weeks)
Study: 27584578
Drug: Arginine deprivation
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine deprivation with ADI-PEG20 (36.8 mg/m2, weekly intramuscular) plus best supportive care (BSC)
Study: 26625989
Drug: 1% subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% subcutaneous lidocaine